AAAAAA
Results:
1-22
|
Results: 22
Authors:
Boelaert, JR
Appelberg, R
Gomes, MS
Blasi, E
Mazzolla, R
Grosset, J
Lounis, N
Soteriadou, K
Thiakaki, M
Taramelli, D
Tognazioli, C
Citation: Jr. Boelaert et al., Experimental results on chloroquine and AIDS-related opportunistic infections, J ACQ IMM D, 26(3), 2001, pp. 300-301
Authors:
Barry, C
Cole, S
Fourie, B
Geiter, L
Gosey, L
Grosset, J
Kanyok, T
Laughon, B
Mitchison, D
Nunn, P
O'Brien, R
Robinson, T
Annick-Mouries, M
Cynamon, M
Duncan, K
Goldberger, M
Gutteridege, W
Kioy, D
Pablos-Mendez, A
Orme, I
Rieder, H
Roscigno, G
Vernon, A
Citation: C. Barry et al., Scientific blueprint for tuberculosis drug development - Global alliance for TB drug development, TUBERCULOSI, 81, 2001, pp. 1-52
Authors:
Lounis, N
Truffot-Pernot, C
Grosset, J
Gordeuk, VR
Boelaert, JR
Citation: N. Lounis et al., Iron and Mycobacterium tuberculosis infection, J CLIN VIRO, 20(3), 2001, pp. 123-126
Authors:
Astagneau, P
Desplaces, N
Vincent, V
Chicheportiche, V
Botherel, AH
Maugat, S
Lebascle, K
Leonard, P
Desenclos, JC
Grosset, J
Ziza, JM
Brucker, G
Citation: P. Astagneau et al., Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak, LANCET, 358(9283), 2001, pp. 747-751
Authors:
Lounis, N
Bentoucha, A
Truffot-Pernot, C
Ji, BH
O'Brien, RJ
Vernon, A
Roscigno, G
Grosset, J
Citation: N. Lounis et al., Effectiveness of once-weekly rifapentine and moxifloxacin regimens againstMycobacterium tuberculosis in mice, ANTIM AG CH, 45(12), 2001, pp. 3482-3486
Authors:
Bentoucha, A
Robert, J
Dega, H
Lounis, N
Jarlier, V
Grosset, J
Citation: A. Bentoucha et al., Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice, ANTIM AG CH, 45(11), 2001, pp. 3109-3112
Authors:
Lounis, N
Truffot-Pernot, C
Bentoucha, A
Robert, J
Ji, BH
Grosset, J
Citation: N. Lounis et al., Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice, ANTIM AG CH, 45(11), 2001, pp. 3229-3230
Authors:
Daniel, N
Lounis, N
Ji, BH
O'Brien, RJ
Vernon, A
Geiter, LJ
Szpytma, M
Truffot-Pernot, C
Hejblum, G
Grosset, J
Citation: N. Daniel et al., Antituberculosis activity of once-weekly rifapentine-containing regimens in mice - Long-term effectiveness with 6-and 8-month treatment regimens, AM J R CRIT, 161(5), 2000, pp. 1572-1577
Authors:
Robert, J
Trystram, D
Truffot-Pernot, C
Carbonnelle, B
Grosset, J
Citation: J. Robert et al., Surveillance of Mycobacterium tuberculosis drug resistance France, 1995-1997, INT J TUBE, 4(7), 2000, pp. 665-672
Authors:
Robert, J
Trystram, D
Truffot-Pernot, C
Cambau, E
Jarlier, V
Grosset, J
Citation: J. Robert et al., Twenty-five years of tuberculosis in a French university hospital: a laboratory perspective, INT J TUBE, 4(6), 2000, pp. 504-512
Authors:
Cambau, E
Truffot-Pernot, C
Boulahbal, F
Wichlacz, C
Grosset, J
Jarlier, V
Citation: E. Cambau et al., Mycobacterial growth indicator tube versus the proportion method on Lowenstein-Jensen medium for antibiotic susceptibility testing of Mycobacterium tuberculosis, EUR J CL M, 19(12), 2000, pp. 938-942
Authors:
Ji, B
Grosset, J
Citation: B. Ji et J. Grosset, Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy, LEPROSY REV, 71, 2000, pp. S81-S87
Authors:
Grosset, J
Citation: J. Grosset, The new challenges for chemotherapy research, LEPROSY REV, 71, 2000, pp. S100-S104
Authors:
Dega, H
Robert, J
Bonnafous, P
Jarlier, V
Grosset, J
Citation: H. Dega et al., Activities of several antimicrobials against Mycobacterium ulcerans infection in mice, ANTIM AG CH, 44(9), 2000, pp. 2367-2372
Authors:
Consigny, S
Bentoucha, A
Bonnafous, P
Grosset, J
Ji, BH
Citation: S. Consigny et al., Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine againstMycobacterium leprae in mice, ANTIM AG CH, 44(10), 2000, pp. 2919-2921
Authors:
Dega, H
Chosidow, O
Barete, S
Carbonnelle, B
Grosset, J
Jarlier, V
Citation: H. Dega et al., Mycobacterium ulcerans infection., ANN MED IN, 151(5), 2000, pp. 339-344
Authors:
Rinder, H
Feldmann, K
Tortoli, E
Grosset, J
Casal, M
Richter, E
Rifai, M
Jarlier, V
Vaquero, M
Rusch-Gerdes, S
Cambau, E
Gutierrez, J
Loscher, T
Citation: H. Rinder et al., Culture-independent prediction of isoniazid resistance in Mycobacterium tuberculosis by katG gene analysis directly from sputum samples, MOL DIAGN, 4(2), 1999, pp. 145-152
Authors:
Flament-Saillour, M
Robert, J
Jarlier, V
Grosset, J
Citation: M. Flament-saillour et al., Outcome of multi-drug-resistant tuberculosis in France - A nationwide case-control study, AM J R CRIT, 160(2), 1999, pp. 587-593
Authors:
Robert, J
Boulahbal, F
Trystram, D
Truffot-Pernot, C
de Benoist, AC
Vincent, V
Jarlier, V
Grosset, J
Citation: J. Robert et al., A national survey of human Mycobacterium bovis infection in France, INT J TUBE, 3(8), 1999, pp. 711-714
Authors:
Peracchia, G
Jensen, AB
Culianez-Macia, FA
Grosset, J
Goday, A
Issinger, OG
Pages, M
Citation: G. Peracchia et al., Characterization, subcellular localization and nuclear targeting of caseinkinase 2 from Zea mays, PLANT MOL B, 40(2), 1999, pp. 199-211
Authors:
Lounis, N
Truffot-Pernot, C
Ji, BH
Grosset, J
Citation: N. Lounis et al., Pharmacokinetics and animal studies of rifapentine in tuberculosis, DRUGS TODAY, 35, 1999, pp. 17-27
Authors:
Grosset, J
Citation: J. Grosset, Which strategies for eradication of tuberculosis ?, B ACA N MED, 183(7), 1999, pp. 1317-1332
Risultati:
1-22
|